AccentHealth adds 1,000 waiting room TVs

Share this article:
AccentHealth buys Havas point-of-care unit, doubles footprint
AccentHealth buys Havas point-of-care unit, doubles footprint

Having doubled its waiting room wallboards franchise by buying Havas's point of care unit, AccentHealth is moving to boost the digital side of its business with its acquisition of MediVista Media's Everwell TV network.

It's a smaller buy, putting AccentHealth video and interactive content in an additional 1,000 waiting rooms and boosting the company's TV network to 13,500 offices. AccentHealth has Health Panels and TV screens in 30,000 offices nationwide. The company is also looking to broaden its media mix throughout its network to include TV, print, literature distribution and some new interactive products.

“We have offices where we have both formats,” said EVP business and product development John Curbishley. “We think they're complimentary. What we're trying to do is allow the client to be able to brand the office with a range of touchpoints in print and digital.”

Clients, said Curbishley, are “really focused on the kind of scale we can provide. They're looking for overall reach, whether print or digital, but also targeted reach into particular conditions, geographies and demographics, and this is a nice deal for us because it extends our reach in all those areas.”

MediVista's Everwell unit will continue to produce health programming, but without its own waiting room network.
Share this article:

Email Newsletters

More in News

BMS Q2 sales slip, Eliquis, Yervoy soar

BMS Q2 sales slip, Eliquis, Yervoy soar

The company attributed part of the Eliquis boost to the BMS-Pfizer DTC and education efforts.

Gilead, Merck HCV marketing battle may be on horizon

Gilead, Merck HCV marketing battle may be on ...

Disclosed in its earnings report yesterday, Gilead may have a card up its sleeve to counter Merck's experimental hep. C combo regimen.

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.